当前位置: X-MOL 学术Clin. Biochem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction.
Clinical Biochemistry ( IF 2.8 ) Pub Date : 2020-03-22 , DOI: 10.1016/j.clinbiochem.2020.03.013
Andreas Sandø 1 , Martin Schultz 1 , Jesper Eugen-Olsen 2 , Lars Køber 3 , Thomas Engstrøm 3 , Henning Kelbæk 4 , Erik Jørgensen 3 , Kari Saunamäki 3 , Lene Holmvang 3 , Frants Pedersen 3 , Hans Henrik Tilsted 5 , Dan Høfsten 3 , Steffen Helqvist 3 , Peter Clemmensen 6 , Kasper Iversen 1
Affiliation  

BACKGROUND Identification of patients at high risk of non-cardiac mortality following ST-segment elevation myocardial infarction (STEMI) could guide clinicians to identify patients who require attention due to serious non-cardiac conditions after the acute phase of STEMI. The purpose of this study was to evaluate if the non-specific and prognostic biomarker of inflammation and comorbidity, soluble urokinase receptor (suPAR), could predict non-cardiac mortality in a cohort of STEMI patients. METHODS SuPAR was measured in 1,190 STEMI patients who underwent primary percutaneous coronary intervention (pPCI). The primary endpoint was non-cardiac mortality, secondary endpoints were cardiac mortality, all-cause mortality, reinfarction and periprocedural acute kidney injury. Backwards elimination of potential confounders significantly associated with the respective outcome was used to adjust associations. RESULTS Patients were followed for a median of 3.0 years (interquartile range 2.5- 3.6 years). Multivariate cox regression revealed that a plasma suPAR level above 3.70 ng mL-1 was associated with non-cardiac and cardiac mortality at hazard ratios 3.33 (95% confidence interval 1.67-6.63, p = 0.001, adjusted for age) and 0.99 (0.18-5.30, p = 0.98, adjusted for previous myocardial infarction and left ventricular ejection fraction), respectively. CONCLUSION In patients with pPCI treated STEMI, suPAR was an independent prognostic biomarker of non-cardiac but not cardiac mortality and may identify patients with high risk of non-cardiac mortality.

中文翻译:

可溶性尿激酶受体可作为经皮冠状动脉介入治疗ST段抬高型心肌梗死患者非心脏死亡的指标。

背景技术对ST段抬高型心肌梗死(STEMI)后非心脏死亡高危患者的识别可以指导临床医师识别在STEMI急性期后因严重的非心脏疾病而需要引起注意的患者。这项研究的目的是评估炎症和合并症的非特异性和预后性生物标志物可溶性尿激酶受体(suPAR)是否可以预测STEMI患者的非心脏死亡率。方法对1190例行原发性经皮冠状动脉介入治疗(pPCI)的STEMI患者进行了SuPAR的测量。主要终点为非心脏死亡率,次要终点为心脏死亡率,全因死亡率,再梗塞和术中急性肾损伤。向后消除与各自结果显着相关的潜在混杂因素用于调整关联。结果随访患者的中位时间为3.0年(四分位间距为2.5-3.6年)。多元Cox回归显示,血浆suPAR水平高于3.70 ng mL-1与非心脏和心脏死亡率相关,危险比为3.33(95%置信区间1.67-6.63,p = 0.001,根据年龄调整)和0.99(0.18- 5.30,p = 0.98,分别针对先前的心肌梗塞和左心室射血分数进行了调整。结论在经pPCI治疗的STEMI患者中,suPAR是非心脏而非心脏死亡的独立预后生物标志物,并可能确定非心脏死亡的高风险患者。结果随访患者的中位时间为3.0年(四分位间距为2.5-3.6年)。多元Cox回归显示,血浆suPAR水平高于3.70 ng mL-1与非心脏和心脏死亡率相关,危险比为3.33(95%置信区间1.67-6.63,p = 0.001,根据年龄调整)和0.99(0.18- 5.30,p = 0.98,分别针对先前的心肌梗塞和左心室射血分数进行了调整。结论在经pPCI治疗的STEMI患者中,suPAR是非心脏而非心脏死亡的独立预后生物标志物,并可能确定非心脏死亡的高风险患者。结果随访患者的中位时间为3.0年(四分位间距为2.5-3.6年)。多元Cox回归显示,血浆suPAR水平高于3.70 ng mL-1与非心脏和心脏死亡率相关,危险比为3.33(95%置信区间1.67-6.63,p = 0.001,根据年龄调整)和0.99(0.18- 5.30,p = 0.98,分别针对先前的心肌梗塞和左心室射血分数进行了调整。结论在经pPCI治疗的STEMI患者中,suPAR是非心脏而非心脏死亡的独立预后生物标志物,并可能确定非心脏死亡的高风险患者。70 ng mL-1与非心脏和心脏死亡率相关,危险比分别为3.33(95%置信区间1.67-6.63,p = 0.001,根据年龄调整)和0.99(0.18-5.30,p = 0.98,针对先前的心肌进行调整)梗死和左心室射血分数)。结论在经pPCI治疗的STEMI患者中,suPAR是非心脏而非心脏死亡的独立预后生物标志物,并可能确定非心脏死亡的高风险患者。70 ng mL-1与非心脏和心脏死亡率相关,危险比分别为3.33(95%置信区间1.67-6.63,p = 0.001,根据年龄调整)和0.99(0.18-5.30,p = 0.98,针对先前的心肌进行调整)梗死和左心室射血分数)。结论在经pPCI治疗的STEMI患者中,suPAR是非心脏而非心脏死亡的独立预后生物标志物,并可能确定非心脏死亡的高风险患者。
更新日期:2020-03-22
down
wechat
bug